Renovascular and renoprotective properties of telmisartan: Clinical utility

International Journal of Nephrology and Renovascular Disease

Volumn 3, Issue , 2010, Pages 33-38

  Ladino, Marco ^a   Schulman, Ivonne Hernandez ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin ii receptor; Hypertension; Kidney diseases; PPAR ; Vascular diseases

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL; TELMISARTAN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LIPOPHILICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; RECEPTOR BLOCKING; RENAL PROTECTION; REVIEW; SIDE EFFECT; SYSTOLIC HYPERTENSION;

EID: 77953411729     PISSN: None     EISSN: 11787058     Source Type: Book Series    
DOI: None     Document Type: Review

References (36)

1. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst. 2009;10(1):1-8.
2. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9:203-210.
3. Elliott HL. Focus on the ONTARGET results. J Hypertens. 2009; 27 Suppl 2:S8-S10.
4. de la Sierra A. Main results and clinical interpretations from the TRANSCEND study. J Hypertens. 2009;27 Suppl 2:S22-S25.
5. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14(7):1738-1747.
6. Urata H, Boehm KD, Philip A. Cellular-localization and regional distribution of an angiotensin-II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
7. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderated kidney disease study. J Am Soc Nephrol. 2005;16(4):1091-1098.
8. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5): 993-1002.
9. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care. 2005;28:757-758.
10. Rong X, Li Y, Ebihara K, et al. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. J Pharmacol Exp Ther. 2009;331(3):1096-1103.
11. Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens. 2008;26(5):973-980.
12. Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor- {gamma} activation. Hypertension. 2009 Oct 12. [Epub ahead of print].
13. Blake R, Raij L, Hernandez Schulman I. Renal protection: are all antihypertensive drugs comparable? Curr Hypertens Rep. 2007;9(5): 373-379.
14. Yuan J, Jia R, Bao Y. Aldosterone upregulates population of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol. 2007;40:180-188.
15. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol. 2004;286:F1059-F1062.
16. Cortinovis M, Perico N, Cattaneo D, Remuzzi G. Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis. 2009;3(2): 133-143.
17. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-ß pathway. Kidney Int. 2006;70:1914-1919.
18. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-ß in kidney disease. Am J Physiol. 1994;266:F829-F842.
19. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19(8):1459-1462.
20. Guo S, Kowalewska J, Wietecha TA, et al. Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol. 2008;19(6):1168-1176.
21. Yao Y, Zou R, Liu X, et al. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma. J Huazhong Univ Sci Technolog Med Sci. 2008;28(5):543-548.
22. Tsunenari I, Ohmura T, Seidler R, et al. Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst. 2007;8(2):93-100.
23. Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma. Hypertens Res. 2009;32(9):765-769.
24. Duan SB, Wang YH, Liu FY, et al. The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model. Acta Radiol. 2009;50(7):754-759.
25. Basile J. Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009;11(5):371-376.
26. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. 2008;358(15):1547-1559.
27. Onuigbo MA. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease a call for caution. Nephron Clin Pract. 2009;113(2): c63-c69.
28. Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009;5(8):436-437.
29. Mann JF, Tobe S, Teo KK, Yusuf S. Is therapy of people with chronic kidney disease ONTARGET? Nephrol Dial Transplant. 2009 Oct 23. [Epub ahead of print].
30. Mazerska M, Mysliwiec M. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors. Adv Med Sci. 2009;54(1):37-40.
31. Doulton TW, Macgregor GA. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. J Renin Angiotensin Aldosterone Syst. 2009 Jul 17. [Epub ahead of print].
32. Littlejohn TW 3rd, Majul CR, Olvera R, et al. Study Investigators. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(4):207-213.
33. Neldam S, Edwards C; ATHOS Study Group. Telmisartan plus HCTZ vs amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2006;15(3):151-160.
34. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens. 2009;27 Suppl 5:S15-S21.
35. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res. 2009;32(11):950-955.
36. Bakris G, Burgess E, Weir M, Davidai G, Koval S. AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364-369.